What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.”In the company’s words, NCT03579836 on ClinicalTrials.gov
- Tested for
- Metastatic Colorectal Cancer, Locally Advanced or Metastatic Pancreatic Cancer, Glioblastoma Multiforme
- Main trialPhase 1/2
- “This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).”In the company’s words, NCT05093907 on ClinicalTrials.gov
Other drugs for Metastatic Colorectal Cancer
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up3
- 30 NovPhase 1/2 trial completes · ClinicalTrials.gov
- 30 NovPhase 1/2 trial completes · ClinicalTrials.gov
- 30 NovPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Nov 2026 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | |
| Phase 1/2Recruiting | 30 Nov 2026 | Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | |
| Phase 1Recruiting | 30 Nov 2026 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026